REGENXBIO, Inc. (RGNX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.94-2.83%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RGNX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue clinical development and initiate BLA submission for RGX-202 with potential accelerated approval in 2H 2027.
Stated as a priority in 2 of last 2 quarters. Revenue grew sharply from $6.4M in 2026-Q1 to $108.0M in 2026-Q2, driven by a $100M milestone payment related to the NAAVIGATE study, reflecting progress in RGX-202 development. Net income improved from a loss of $90.1M in 2026-Q1 to a profit of $22.7M in 2026-Q2. Management's trajectory on RGX-202 clinical advancement and BLA submission is delivering with strong financial milestones.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027”
“Positive topline results from pivotal Phase III AFFINITY DUCHENNE study of RGX-202; BLA submission planned”
Progress clinical trials for sura-vec in wet AMD and diabetic retinopathy with key data expected in Q4 2026 and ongoing Phase IIb/III NAAVIGATE study.
Stated as a priority in 2 of last 2 quarters. Clinical progress includes dosing the first patient in the NAAVIGATE study and anticipation of pivotal topline data in Q4 2026. While no direct revenue impact is yet reported, management's focus on advancing sura-vec toward regulatory submissions is consistent and ongoing.
“First patient dosed in Phase IIb/III NAAVIGATE study; topline data from ATMOSPHERE and ASCENT pivotal trials expected in Q4 2026”
“Sites activated in pivotal Phase IIb/III study for diabetic retinopathy; first patient dosing expected Q2 2026”
Address FDA regulatory feedback on RGX-121 and resolve legal disputes such as the GSK sublicense mediation settlement.
Ensure sufficient liquidity through milestone payments and capital raises to support operations into Q4 2027.
Stated as a priority in 3 of last 3 quarters. Cash and equivalents declined from $240.9M at 2025-Q4 to $105.5M at 2026-Q2 due to operating use, but a $100M milestone payment and $108M public offering proceeds in July 2026 increased pro forma cash to approximately $313M. Management's guidance to fund operations into Q4 2027 is consistent with these liquidity events, indicating delivery on cash runway maintenance.
“Cash, cash equivalents and marketable securities of $105.5M as of June 30, 2026 plus $100M milestone and $108M offering proceeds fund operations into Q4 2027”
“Cash, cash equivalents and marketable securities of $150.5M as of March 31, 2026 to fund operations into early 2027”
“Cash, cash equivalents and marketable securities of $240.9M as of December 31, 2025 to fund operations into early 2027”
Appoint new independent director with biotechnology investing and capital allocation experience to support growth.
Newly stated in 2026-Q3 (August 2026). The appointment of Greg Ciongoli to the Board adds financial and strategic expertise to support REGENXBIO's growth phase. This is a one-time event with no direct financial metrics but aligns with management's stated focus on strengthening governance.
Over the trailing year it converted 0.66x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
11 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.